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Abstract
Objective: Dementia with Lewy bodies is an a-synucleinopathy characterized
by neocortical Lewy-related pathology (LRP). We carried out a genome-wide
association study (GWAS) on neocortical LRP in a population-based sample of
subjects aged 85 or over. Methods: LRP was analyzed in 304 subjects in the
Vantaa 85+ sample from Southern Finland. The GWAS included 41 cases with
midbrain, hippocampal, and neocortical LRP and 177 controls without mid-
brain and hippocampal LRP. The Medical Research Council Cognitive Function
and Ageing Study (CFAS) material was used for replication (51 cases and 131
controls). Results: By analyzing 327,010 markers the top signal was obtained at
the HLA-DPA1/DPB1 locus (P = 1.29 9 107); five other loci on chromosomes
15q14, 2p21, 2q31, 18p11, and 5q23 were associated with neocortical LRP at
P < 105. Two loci were marked by multiple markers, 2p21 (P = 3.9 9 106,
upstream of the SPTBN1 gene), and HLA-DPA1/DPB1; these were tested in the
CFAS material. Single marker (P = 0.0035) and haplotype (P = 0.04) associa-
tions on 2p21 were replicated in CFAS, whereas HLA-DPA1/DPB1 association
was not. Bioinformatic analyses suggest functional effects for the HLA-DPA1/
DPB1 markers as well as the 15q14 marker rs8037309. Interpretation: We iden-
tified suggestive novel risk factors for neocortical LRP. SPTBN1 is the candidate
on 2p21, it encodes beta-spectrin, an a-synuclein binding protein and a compo-
nent of Lewy bodies. The HLA-DPA1/DPB1 association suggests a role for anti-
gen presentation or alternatively, cis-regulatory effects, one of the regulated
neighboring genes identified here (vacuolar protein sorting 52) plays a role in
vesicular trafficking and has been shown to interact with a-synuclein in a yeast
model.
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Introduction
Analysis of abnormal protein accumulation plays an
important role in the neuropathological classification of
neurodegenerative disorders. Alzheimer’s disease (AD) is
characterized by b-amyloid plaques and intracellular neu-
rofibrillary tangles, composed of hyperphosphorylated tau
protein. Parkinson’s disease (PD) is characterized by
intraneuronal Lewy bodies and Lewy neurites (Lewy-re-
lated pathology, LRP) in the brainstem. The main
component of Lewy bodies is conformationally modified
a-synuclein.1,2 Anatomical spreading of the LRP into
neocortex often results in cognitive and behavioral symp-
toms.
Neocortical LRP is found in at least three clinically
defined conditions: in PD with dementia, in dementia
with Lewy bodies (DLB) and in Lewy body variant of
AD. These disorders are considered to constitute a con-
tinuum with varying weighting of the symptoms and neu-
ropathological features. Yoshimura suggested that an
intermediate phenotype between AD and PD represents a
disorder of its own, which he termed “Diffuse Lewy body
disease”.3 However, clinical characterization of this disor-
der has been difficult and no specific biomarkers have
been available. These ambiguities are reflected in the vari-
ous terms that have been used, the most common of
which is DLB. Neuropathological classification of Lewy
body disorders has also been challenging, the criteria have
been widely debated and subject to many revisions. Today
both classical Lewy bodies and Lewy neurites are regarded
as neuropathological hallmarks of DLB and termed as
“LRP.” The most recent proposal classifies LRP as brain-
stem, limbic, or neocortical-predominant categories based
on the anatomical spreading.4 Virtually all subjects with
neocortical LRP have brainstem and limbic pathology,
too.
There has been significant progress in deciphering the
genetic background of AD and PD. However, the “inter-
mediate phenotype” DLB, has remained genetically less
well characterized. Most DLB patients are sporadic, but a
few DLB families have been identified. Mutations in PD-
related genes a-synuclein (SNCA), Leucine-rich repeat
kinase-2 (LRRK2), and Glucocerebrosidase-A (GBA) have
been described in DLB patients with onset before age
65.5–11 Overlap with AD is found, too, both pathologically
and genetically. Cortical Lewy bodies are relatively com-
monly found in combination with AD pathology in
patients diagnosed as AD. Amyloid precursor protein
(APP) and Presenilin-2 (PSEN-2) mutations typically lead
to early-onset AD, but the phenotypic spectrum may
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include features of DLB.12,13 In addition to the genetic
findings overlapping with PD or AD, two different pre-
sumably pathogenic b-synuclein (SNCB) mutations have
been found in two unrelated DLB patients14 and, in a
Belgian family, linkage between DLB and chromosome
2q35–q36 has been reported.15 Genetic analyses of spo-
radic late-onset DLB cases have identified associations
with both AD and PD genes, such as APOE, SNCA,and
SCARB2.16–18
Despite these advances, the genetic background of the
common late-onset sporadic form of DLB has remained
unclear. Here, we have carried out a neuropathology-
based genome-wide association study (GWAS) using the
presence of neocortical LRP as the phenotypic trait in a
population-based setting. Such analysis is free from ambi-
guities of clinical diagnostics (differentiation between PD-
dementia, DLB, and Lewy body variant of AD) and from
selection bias often involved in patient materials collected
from referral-based institutions.
Subjects and Methods
Subjects in Vantaa 85+
The Vantaa 85+ study includes all 601 persons aged
85 years or over who were living in the city of Vantaa
(Southern Finland), on 1 April 1991. The study design
has been described in detail earlier.19,20 Autopsies were
carried out in 304 subjects, median age at death was
92.2 years (females 83%). The study was approved by the
Ethical review committee of the City of Vantaa. The use
of the health and social work records and death certifi-
cates was approved by the Finnish Health and Social
Ministry by the Finnish Ministry of Social Affairs and
Health. The collection of the tissue samples at autopsy,
and their use for research, was approved by the National
Authority for Medicolegal Affairs and coordinating ethical
committee of the Helsinki and Uusimaa Health care dis-
trict (74/13/03/00/2014). Consent for participation in the
study and autopsy was obtained from the subjects and/or
their nearest relatives.
Pathology in Vantaa 85+
The brains of the autopsied subjects were fixed in phos-
phate-buffered 4% formaldehyde for at least 2 weeks
before sampling. Tissue samples were obtained following
recommendations of the first Consortium for DLB
(CDLB) workshop for assessing LRP.21 The analysis of
LRP has been described in detail earlier.19 Briefly, a two-
step analysis was used. First, sections from the midbrain
and hippocampus were stained with the hematoxylin and
eosin method and with immunohistochemical method for
a-synuclein (primary antibody from Transduction Labo-
ratories, Lexington, KY, clone42, mouse monoclonal,
diluted 1:800). Second, if any LRP was detected in the
screened areas, immunohistochemical staining for a-synu-
clein was performed on samples from the temporal, fron-
tal, and parietal neocortex and cingulate gyrus.
Semiquantitative scoring of LRP (none, mild, moderate,
severe, and very severe) and assignment of the type of
LRP (none, brainstem-predominant, limbic, diffuse neo-
cortical) was performed by a single investigator (M.
Oinas) following the modified Third CDLB guidelines for
diagnosis.21 There were 47 subjects (15%) with neocorti-
cal LRP in the 304 brains analyzed in the Vantaa 85+
study; 20 of these 47 had a Braak stage V–VI.19 Genotyp-
ing was possible in 41 subjects (cases) with diffuse neo-
cortical LRP and in 177 subjects (controls) with no LRP
in the brainstem and hippocampus.
CFAS study
The Medical Research Council Cognitive Function and
Ageing Study (CFAS) is a longitudinal, prospective,
population-based cohort study undertaken in six UK
centers initiated in 1989 (www.cfas.ac.uk). It has been
previously described.22 The study included a random
sample of 18,226 people 65 years and over. A subsam-
ple of respondents was asked whether they, with family
support, were willing to consent to brain donation after
their death. Median age at death for CFAS brain
donors was 87 years (females 41%, donations ongoing).
The burden and anatomic distribution of a-synuclein
was investigated in a subsample of donations (in two
of the six centers) before July 2003 (n = 208). The
method to assess LRP has been previously described.23
A hierarchical sampling strategy, based on evaluation of
the midbrain (substantia nigra), medulla, and amygdala,
was used to immunohistochemically detect a-synuclein
in this cohort (primary monoclonal antibody LB509;
Zymed Laboratories Inc., San Francisco, CA). If an a-
synuclein immunoreactive profile was found in a
screening area a further five areas recommended by the
First CDLB 1996,21 the same as in the Vantaa 85+
study, were investigated. There were 54 subjects (cases)
who showed LRP in at least one of the three regions
brainstem, limbic, or neocortex (brainstem only n = 24,
limbic n = 2, brainstem + limbic n = 9, neocortical
n = 19) and 138 subjects (controls) who did not show
LRP in the three aforementioned regions23 (Fig. 2
therein). The controls included the brainstem-negative
amygdala-predominant group (n = 22) because subjects
with this type of pathology were classified as control in
the Vantaa 85+ material (they were negative for brain-
stem and hippocampal LRP). Genotyping was successful
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in 51 cases with LRP and in 131 controls. Because of
the lower sensitivity of the antibody used in the CFAS
study,4 and lower number of subjects with neocortical
LRP (19/208 [9%] overall; genotyping successful in 17
cases), we chose to pool the subjects with brainstem,
limbic, and neocortical LRP for the genetic analyses.
Thus, we increased the number of cases at the expense
of the regional specificity of LRP.
Genotyping
Infinium Human370 BeadChips (Illumina, San Diego
CA), which assay 345,111 single-nucleotide polymor-
phisms (SNPs) across the genome, was used for genotyp-
ing the Vantaa 85+ samples. Standard quality control
procedures were applied as follows: exclusion of samples
with SNP call rates of less than 95%, cryptic relatedness,
non-European ancestry, minor allele frequency (MAF) less
than 0.01, and Hardy–Weinberg equilibrium P value of
less than 0.001 as reported.24 Two-hundred and eighteen
subjects with 327,010 SNPs, including sex-chromosomal
SNPs, were analyzed. Bonferroni corrected threshold for
genome-wide significance with this data would be
1.56 9 107 (a = 0.05/327,010 SNPs). Genotyping of the
CFAS study was carried out by Sanger sequencing with
the following forwards (F) and reverse (R) primers:
rs9277685-rs9277682-F 50-tct ggt ggt cca att tcc-30;
rs9277685-rs9277682-R 50-cca ctg act cca agt atg-30;
rs2071349-F1 50-gag gtg tgg cag aat tgg-30, rs2071349-R1
50-tct gtg acc ctg gga ttg-30; rs2301226-F1 50-ttg cag ggt
tgct gga gat g-30; rs2301226-R1 50-cca agg aga cag ttg cca
gaa g-30; rs9277334-F1 50-ata tgg gca tgg cgt gat gag-30;
rs9277334-R1 50-tgg aag tgg gta cgt cac aac-30; rs4671212-
F1 50-ttc aca gtg tgg agc aga ac-30; rs4671212-R1 50-agc
ctc tgt ctc tac tca cta c-30; rs4315567-F1 50-cct cct atg tcc
tcc ctt aac-30; rs4315567-R1 50-tag tct gtg ctg cca gat g-30.
HLA-DPB1 typing was carried out by sequence-specific
oligonucleotide probes using OLERUP SSP DPB1 kit
(www.olerup-ssp-com). SPTBN1 and C2ORF73 re-se-
quencing was carried out by Sanger sequencing of PCR
products using the following primers. SPTBN1 promoter-
exon 1: 50-cgt gaa att ggc cct ctc cg-30 and 50-tcc cgc atc
atc cgt ga tacc-30; SPTBN1 exon 2: 50- gat atc ggc tca cta
caa cct-30 and 50-ttc agg cca gct caa gaa aga tc-30; SPTBN1
exon 3: 50- gca ggt gaa gac ggt cat tgc-30 and 50-cat gtg
ctc tgg gag gat aca-30; C2ORF73 promoter-exon 1: 50-cca
ctc ctt act cac caa ac-30 and 50-cgc tca gcc aac tgg aaa tta
g-30; C2ORF73 exon 2: 50- aac aca aag ccc ttt atc g-30 and
50- cac tta gct cat tcc tag aac-30; C2ORF73 exon 3: 50- ggc
tag gga cta aaa ctt c-30 and 50- tgg tgg caa caa caa tga g-
30; C2ORF73 exons 4–5: 50-cac cat gcc tga cca tat tg-30
and 50- gcc tac tgc ctg gtt tta tc-30; C2ORF73 exon 6: 50-
ctg gct ttg cct aat ttc-30 and 50- agt acc caa atg gta ctg-30,
C2ORF73 exons 7–8: 50-cgg cgg aga tgg cag tat atg ac-30
and 50- gtc aga agg cag aca gcc aag ag-30.
Statistical analyses and bioinformatics
Whole genome associations were calculated with PLINK
(allelic chi-square test without covariates, and by logistic
regression with age, sex, and AD-pathology as co-variates
http://pngu.mgh.harvard.edu/purcell/plink/). Beadstudio
was used in the first quality control to determine that a
beadchip had worked and transferring data from bead-
chips to PLINK format. Haplotype association and link-
age disequilibrium structures were calculated with the
Haploview software. In silica quantitative trait locus
(QTL) analysis methods was carried out in the North
American Brain Expression Consortium (NABEC) and
United Kingdom Brain Expression Consortium (UKBEC)
data.25–27 Brain mRNA expression and DNA methylation
have been assayed in brains without determinable neu-
ropathological evidence of disease. Expression of mRNA
was assayed using Illumina HumanHT-12 v3 Expression
Beadchips, methylation was assayed on bisulfite converted
DNA using the Illumina Infinium HumanMethylation27
BeadChips. Genotyping was performed using Illumina
HumanHap550 v3, Human610-Quad v1 or Human660W-
Quad v1 Infinium Beadchips. The combined annotation-
dependent depletion (CADD) tool28 was also use to ana-
lyze possible functionality of the top SNPs.
Results
In the GWAS we compared the 41 cases with neocortical
LRP to the 177 controls without midbrain and hippocam-
pal LRP. Five association peaks with P < 105 were found
(Fig. 1, Table 1). Two of these signals showed multiple
flanking-associated SNPs, one on chromosome 2p21
between the C2ORF73 and beta-spectrin family gene
(SPTBN1) (P = 3.86 9 106, allelic test), the other on
chromosome 6p21 at the HLA-DPA1 and -DPB1 loci
(P = 1.29 9 107, allelic test). Logistic regression using
AD pathology as a covariate did not abolish the five asso-
ciation peaks, suggesting that these associations are largely
driven by neocortical LRP (Table S1). The Q-Q plot indi-
cates that the number of observations at P < 104 is
higher than expected (Fig. S1). By imputation using MAF
filter >0.02 and r2 > 0.30 we did not detect any associa-
tion reaching genome-wide significance (threshold set at
5 9 108 for imputation-derived signals).
A list of all SNPs with a P < 103 (n = 336) are shown
in Table S2. The results at the previously implicated DLB-
loci (GBA, LRRK2, SNCA, SNCB, 2q35-q36, APP, PSEN2,
APOE, SCARB2) are provided in Table S3, of these, the
lowest P-value was observed with a SNP (rs12694814,
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P = 0.0011) within the delta/notch-like EGF repeat con-
taining (DNER) gene on 2q36. APOE e4 was nominally
associated with neocortical LRP (P = 0.004, Table S3).
However, when a logistic regression analysis was applied
with AD pathology as a covariate, this association was lost
(P = 0.5279, Table S1) suggesting that the APOE e4 asso-
ciation is largely driven by concomitant AD pathology. A
more thorough analysis on AD and PD loci in neocortical
LRP and its pathological subtypes using other pathologies
as covariates will be reported separately (L. Myllykangas
et al., unpubl. ms.).
A more detailed view to the chromosome 2p21 peak is
given in Figure 2. Based on the haplotype block structure
the associated block is between the C2ORF73 and
SPTBN1 genes. A 9-SNP haplotype within this block was
associated with neocortical LRP (P = 5.2 9 107). This
Table 1. P-values, positions, nearest gene, frequencies and OR of all the SNPs associated with Lewy-related pathology at P < 105 in the Vantaa
85+ genome-wide association study.
Chr SNP Position Gene P Risk allele Risk allele frequency OR (95% CI)
6 rs9277685 33196062 HLA-DPB1 1.29E-07 A 0.214485 5.31 (2.59 to 10.91)
6 rs9277334 33138090 HLA-DPA1 9.65E-07 C 0.192308 5.27 (2.56 to 10.81)
6 rs2301226 33142574 HLA-DPA1 1.16E-06 T 0.19346 3.75 (2.15 to 6.54)
15 rs8041665 35937471 Intergenic 1.39E-06 A 0.045726 7.41 (2.92 to 18.81)
15 rs8037309 35937730 Intergenic 1.39E-06 T 0.045726 7.41 (2.92 to 18.81)
6 rs4713610 33215933 HLA-DPB1 1.51E-06 G 0.207756 3.51 (2.02 to 6.11)
6 rs2071349 33151498 HLA-DPB1 2.08E-06 G 0.197802 3.63 (2.08 to 6.32)
6 rs9277656 33192126 HLA-DPB1 2.50E-06 T 0.252174 3.41 (2.01 to 5.79)
2 rs7595929 54479744 SPTBN1 3.86E-06 T 0.301493 3.23 (1.93 to 5.39)
2 rs4315567 54509448 SPTBN1 4.86E-06 T 0.273256 3.21 (1.92 to 5.38)
2 rs3796058 172650694 MAP10 4.97E-06 C 0.258621 3.23 (1.92 to 5.44)
6 rs2395349 33191112 HLA-DPB1 5.01E-06 A 0.258621 3.27 (1.93 to 5.52)
6 rs9277682 33195662 HLA-DPB1 5.01E-06 C 0.279805 3.27 (1.93 to 5.52)
18 rs1472194 1200675 Intergenic 5.19E-06 G 0.137662 8.06 (2.84 to 22.87)
5 rs6872138 116447410 Intergenic 6.40E-06 G 0.171123 3.82 (2.07 to 7.45)
5 rs1459086 116416478 Intergenic 7.15E-06 T 0.214485 3.54 (1.99 to 6.30)
OR, odds ratios; SNP, single-nucleotide polymorphism.
Figure 1. Manhattan plot of Lewy-related pathology in the Vantaa 85+ study, showing log10 P-values for the 327,010 markers ordered by their
chromosomal position. The horizontal lines indicate the threshold for genome-wide significance (P = 1.56 9 107) and P = 105.
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haplotype was ~48 kb wide and was located upstream of
the SPTBN1 including its promoter. The whole C2ORF73
gene and the SPTBN1 promoter and exons 1–3 (located
within ~100 kb from the two top SNPs) were re-se-
quenced in three cases with this haplotype. One missense
variation was found in the C2ORF73 gene (Asn29His,
rs55714450). No sequence variations were found in the
SPTBN1 promoter and exons 1–3. The rs5571450 allele A
associated with neocortical LRP (allelic test v2 = 8.18,
1 df, P = 4.2 9 103, recessive test v2 = 12.7, 2 df,
P = 3.6 9 104).
The associated haplotype block in the HLA region was
~150 kb wide and included HLA-DPA1 and -DPB1 genes
(Fig. 3). A six-SNP haplotype was associated with LRP
(P = 1.10 9 107, markers listed in Fig. 3) and another
haplotype defined by the same six SNPs was associated
with protection against neocortical LRP (P = 0.005). Four
individuals homozygous for the predisposing haplotype
and three individuals homozygous for the putative pro-
tective haplotype were typed for HLA-DPB1. All carriers
of the predisposing haplotype were HLA-DPB1*0201
homozygotes. All carriers of the protective haplotype were
carriers of HLA-DPB1*0401, two homozygous, one
heterozygous.
We analyzed two 2p21 SNPs and five HLA-DPA1/DPB1
SNPs in the CFAS material, three additional SNPs failed
in genotyping by Sanger sequencing. One of the chromo-
some 2p21 SNPs (P = 0.0035) and haplotypes associated
with either predisposition to (P = 0.044) or protection
from LRP (P = 0.011) were replicated in the CFAS mate-
rial (Table 2). The joint analysis of the predisposing hap-
lotype strengthened the association (P = 4.0 9 107).
The HLA-DPA1/DPB1 SNPs did not show nominally sig-
nificant associations with neocortical LRP in the CFAS
material (Table 2).
To analyze possible functional effects of the 16 top
SNPs in the GWAS (P < 105 shown in Table 1), we ana-
lyzed possible association of these SNPs with chromoso-
mal methylation and mRNA expression (cis QTLs) from
the NABEC-UKBEC frontal cortex and cerebellum
data.25–27 The mRNA expression analysis (data shown in
Table S4) suggest that the HLA-DPA1/DPB1 locus risk
alleles modify the expression of the Vacuolar protein sort-
ing 52 (VPS52, downregulation), Beta 1,3 galactosyltrans-
ferase, polypeptide 4 (B3GALT4, upregulation) and
Transporter associated with antigen processing binding
protein (TAPBP, upregulation) genes, which are located
160–220 kb centromeric from HLA-DPB1. The methyla-
tion analysis indicates that the HLA-DPA1/DPB1 locus
SNPs modify the methylation of VPS52. We also analyzed
CADD scores28 of the same 16 top SNPs. The chromo-
some 15 rs8037309 showed a significant CADD-score 29.3
suggesting a possible functional role for this intergenic
SNP (Table S4).
Discussion
Although DLB was first recognized as a disease entity
already 30 years ago, understanding of its pathogenesis
and genetic background is still very limited. The develop-
ment of neocortical LRP is part of a spectrum of neu-
rodegenerative mechanisms that overlaps with both AD
and PD.21,29 Accordingly, many of the previous genetic
findings implicate AD and PD genes.5–18 A GWAS meta-
analysis was recently reported in which LRP as a trait was
analyzed slightly differently from our study by dichotomy
(absent vs. present in any brain region), three category
endpoint (none, brainstem-predominant, and all other
regions or not specified) or five category endpoint (none,
brainstem-predominant, limbic, neocortical, and other
regions or not specified).18 Using these endpoints APOE
e4 associated with LRP at the genome-wide significant
level illustrating a strong link with a major AD gene.18 In
our data the APOE association was driven by the subjects
with concomitant AD pathology suggesting that a sub-
group reminiscent of the “Lewy body variant of AD”
would be responsible for the APOE signal in the Vantaa
85+ material.
Here, we report the results of a GWAS using “neocorti-
cal LRP versus none” as the endpoint in a population-
based neuropathologically examined material of very
elderly subjects (Vantaa 85+). At least two interesting loci
were revealed: the chromosome 2p21 locus and the chro-
mosome 6p21/HLA-DPA1/DPB1 locus. The top SNPs
were not replicated in the CFAS material, but nominally
significant associations were found with the chromosome
2p21 locus markers and haplotypes (Table 2). The repli-
cation analysis of the HLA-DPA1/DPB1 locus did not
yield nominally significant associations in the CFAS mate-
rial. A few other potentially interesting loci were detected
at P < 105 (Table 1) and a larger list of other possible
risk loci (P < 103) is provided in Table S2.
It is possible that the differences in the HLA-DPA1/
DPB1 results reflect the differences in the study popula-
tions or neuropathological methods. First, the CFAS study
population is somewhat younger than the Vantaa 85+
and with more males. The risk allele profile may vary as a
function of age and sex. Second, the British population is
genetically more heterogeneous than the Finns, thereby
genetic association maybe harder to detect. Third, differ-
ent methods were used when assessing the LRP, which
may have affected the sensitivity of detecting LRP.4 The
neuropathological phenotype of the cases was less purely
neocortical in the CFAS material as in the Vantaa 85+.
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Figure 2. Regional association plot and linkage disequilibrium structure of the chromosome 2p21 markers at the C2ORF73 and SPTBN1 genes.
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Figure 3. Regional association plot and linkage disequilibrium structure of the chromosome 6 markers at the HLA-DPA1, HLA-DPB1, and
COL11A2 genes. Haplotype analysis was performed with the following six markers: rs2395349, rs9277656, rs3117035, rs1883414, rs9277682,
and rs9277685. The predisposing haplotype was defined by the alleles ATACCA and the putative protective haplotype by the alleles GGGCTG.
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The chromosome 2p21 peak is located between the
C2ORF73 and SPTBN1 genes. The whole C2ORF73 gene
and SPTBN1 promoter and exons 1–3 were re-sequenced.
A common nonsynonymous (Asn29His) variant was found
in the C2ORF73 gene, whereas no sequence variations were
found in the SPTBN1. Although the Asn29His variant was
associated with the disease in our sample, we consider
SPTBN1 the more likely candidate in this region. First,
SPTBN1 is known to be expressed in the brain and neu-
rons, whereas C2ORF73 exhibits a restricted expression
pattern; based on the expressed sequence tag and RNA
sequencing data the highest expression levels is found in
testis and fetus (https://www.ebi.ac.uk/gxa/experiments/E-
MTAB-513). We did not detect any mRNA expression of
C2ORF73 in RT-PCR experiments of frontal cortex speci-
men, whereas SPTBN1 mRNA expression was readily
detected (data not shown). Second, SPTBN1 is functionally
linked with Lewy bodies and a-synuclein. SPTBN1 has
been identified as one of the constituents of neocortical
Lewy bodies30 and it has been recently shown that SPTBN1
binds directly to a-synuclein.31 Furthermore, in dopamin-
ergic neuronal cells SPTBN1 and a-synuclein are both
functionally involved in the modulation of neurite out-
growth.31 Given the direct interaction between SPTBN1
and a-synuclein, SPTBN1 is an attractive candidate gene
for modulating neocortical LRP. SPTBN1 is a 247-kDa
cytoskeletal protein, which forms heterodimers with a-
spectrins. These heterodimers have the capacity to bind to
membranes at the cytoplasmic surfaces and they also bind
to other cytoskeletal proteins such as actin and ankyrin.
Presynaptic SPTBN1/a-spectrin heterodimers play an
important physiological role in stabilization of synapses32
and are also involved with the regulation of exocytosis of
neurotransmitters.33,34 We did not find any sequence vari-
ants that would lead to amino acid changes in the SPTBN1
exons 1–3 located within 100 kb of the top SNPs. Nor
were such variants (with frequency of >2%) reported in
the whole SPTBN1 gene in the Exome Aggregation Con-
sortium database (http://exac.broadinstitute.org/). These
data indicate that SPTBN1 exhibits very little common
amino acid variation, and it is likely that the chromosome
2p21 risk locus regulates the expression of SPTBN1.
The HLA-DPA1/DPB1 region has previously been asso-
ciated with allergic and immune-mediated disorders.
Interestingly, recent studies have reported an association
between PD and another HLA locus HLA-DRA/
DRB1.35,36 The association of the HLA-DPA1/DPB1 locus
with neocortical LRP and the association of the HLA-
DRA/DRB1 locus with PD most likely represent two sep-
arate association signals. There was no linkage disequilib-
rium between the associated HLA-DPA1/DPB1 SNPs
with HLA-DRA/DRB1 markers, and we did not find any
association at P < 0.01 between neocortical LRP and the
HLA-DRA/DRB1 locus (data not shown). The predispos-
ing HLA-DPA1/DPB1 haplotype harbored the HLA-
DPB1*0201 allele, whereas the putative protective haplo-
type harbored the DPB1*0401 allele. Similar pattern of
predisposition (DPB1*0201) and protection
(DPB1*0401) has been reported in chronic beryllium
disease, which is a granulomatous lung disorder caused
by hypersensitivity to beryllium and leads to the accu-
mulation of beryllium-specific CD4 T lymphocytes in the
lung upon exposure to beryllium metal.37 The role of
metal exposure has been a subject of debate in the devel-
opment of a-synuclein pathology since the discovery of
increased amounts of iron, zinc, and aluminim in PD
patients’ substantia nigra.38 In addition to the immune-
related functions, the HLA-DPA1/DPB1 locus SNPs may
regulate expression of nearby genes. Based on the cis
QTL analysis mRNA expression of VPS52, TAPBP, and
B3GALT4 as well as methylation of VPS52 were modu-
lated by these SNPs. This may be of interest because
VPS52 yeast homologue has been shown to be part of a
Golgi-associated retrograde protein (GARP) complex.39
Disruption of GARP-complex via VPS52 deletion has
been shown to increase alpha-synuclein induced vesicle
aggregation and toxicity in a yeast model.40
The GWAS in the Vantaa 85+ material is based on a
small number of cases and controls (41 cases vs. 177
controls), which limits the statistical power. This limita-
tion is, however, compensated by the precision of the








rs4671212 0.012 0.0035 3.6 9 105
rs43155671 2.6 9 106 0.12 3.1 9 106
GT-haplotype 9.5 9 107 0.044 4.0 9 107
TG-haplotype 0.016 0.011 1.2 9 104
Chromosome 6
rs9277334 1.4 9 106 0.48 9.7 9 105
rs2301226 1.6 9 106 0.24 2.3 9 105
rs2071349 2.8 9 106 0.075 5.4 9 106
rs9277682 5.9 9 106 0.97 1.1 9 103
rs9277685 1.1 9 107 0.97 2.2 9 104
The two SNPs that best separated the chromosome 2 locus haplotype
(rs7595929, rs4315567) were selected for genotyping by sequencing
in the CFAS material. One of the SNPs (rs7595929) failed in sequenc-
ing but another SNP rs4671212, was located in the sequenced area.
The GT-haplotype was associated with predisposition to and the TG-
haplotype with protection from Lewy-related pathology in the Vantaa
85+ and CFAS materials. Seven SNPs with a P-value under 105 were
selected from the HLA-DPA1/DPB1 locus, two of the SNPs failed in
sequencing in the CFAS material. CFAS, Cognitive Function and Age-
ing Study; SNPs, single-nucleotide polymorphisms.
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neuropathological phenotype providing a good contrast
of cases versus controls in the phenotypic axis (here
spreading of LRP). Previous analysis on the association of
neocortical beta-amyloid quantity with APOE e4 has
shown good statistical power in 282 subjects of the Van-
taa 85+ (P = 4.9 9 1017)20 illustrating the power gained
by the phenotypic precision. It is clear that the present
results, although hitting interesting genes, are preliminary
and should be confirmed in similarly phenotyped elderly
cases and controls.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. QQ plot for the P-values observed in the gen-
ome-wide association study of neocortical Lewy-related
pathology in Vantaa 85+. Observed P-values of the SNPs
are plotted against the expected P-values.
Table S1. Top signals (P < 105) and APOE e4 analyzed
by logistic regression using age, sex, and Alzheimer
pathology (Braak, CERAD) as covariates. Logistic regres-
sion results in loss of power as compared to pure allelic
test shown in Table 1.
Table S2. Chromosomal positions, nearest genes and P-
values of all 336 SNPs associated with neocortical Lewy-
related pathology at P < 103 in the Vantaa 85+ study.
Table S3. Genes, chromosomal regions, SNPs and P-val-
ues in the genome-wide association study of Lewy-related
pathology in Vantaa 85+ in previously implicated genes
and regions.
Table S4. Significant cis eQTL results of the top 16 SNPs
in methylation and expression derived from the NABEC-
UKBEC frontal cortex and cerebellum data. CADD results
are shown in the second sheet of the table. Two separate
sheets: eQTL and CADD.
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